Clinical Trials Logo

Unresectable Stage III NSCLC clinical trials

View clinical trials related to Unresectable Stage III NSCLC.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04982549 Recruiting - Clinical trials for Unresectable Stage III NSCLC

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Start date: January 21, 2021
Phase: Phase 2
Study type: Interventional

This is a prospective, multi-center, single arm study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + SoC CRT) in patients with locally advanced, unresectable NSCLC (Stage III).